Natural Killer Cell Therapy

BIOLOGICAL12 trials

Sponsors

Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, M.D. Anderson Cancer Center, St. Jude Children's Research Hospital, Sumithira Vasu

Conditions

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia (ALL)Acute Lymphoblastic Leukemia in RemissionAcute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Early Phase 1

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

RecruitingNCT07144384

Kirsten JohnsonSkin Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Squamous Cell Carcinoma

Start: 2025-10-16End: 2026-12-31Target: 40Updated: 2026-02-13

Phase 1

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

CompletedNCT00789776

Fred Hutchinson Cancer CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma +13

Start: 2008-10-13End: 2017-05-31Updated: 2020-01-31

NK Cells in Cord Blood Transplantation

M.D. Anderson Cancer CenterAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission +22

Start: 2013-05-03End: 2021-11-30Updated: 2020-02-11

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

CompletedNCT01904136

M.D. Anderson Cancer CenterAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations +6

Start: 2014-04-22End: 2022-02-28Updated: 2024-01-24

Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

CompletedNCT02271711

M.D. Anderson Cancer CenterRecurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma

Start: 2015-03-17End: 2020-08-28Updated: 2020-09-02

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT02316964

Sumithira VasuAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) +5

Start: 2015-04-21End: 2019-12-20Updated: 2020-03-09

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

RecruitingNCT04848064

John ReneauRecurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma +1

Start: 2022-05-06End: 2027-01-30Target: 12Updated: 2026-02-10

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

RecruitingNCT05588453

Kari KendraClinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma +1

Start: 2023-03-01End: 2026-04-15Target: 30Updated: 2026-01-12

Phase 2

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

TerminatedNCT00450983

Fred Hutchinson Cancer CenterGraft Versus Host Disease, Leukemia, Myelodysplastic Syndromes

Start: 2006-12-31End: 2010-07-31Updated: 2017-05-24

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

CompletedNCT00526292

Memorial Sloan Kettering Cancer CenterLeukemia, Myelodysplastic Syndromes

Start: 2007-08-31End: 2015-07-31Updated: 2016-02-12

Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma

CompletedNCT01729091

M.D. Anderson Cancer CenterPlasma Cell Leukemia, Plasma Cell Myeloma

Start: 2013-06-10End: 2024-06-25Updated: 2025-05-09

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

TerminatedNCT02259348

St. Jude Children's Research HospitalAcute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML) +4

Start: 2014-10-31End: 2016-03-31Updated: 2017-05-30

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).

Journal of Clinical Oncology2022-06-014 citations

A Pilot Phase I Trial of IL-21 Expanded Ideal-Donor Natural Killer (NK) Cells in Combination with Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas (CTCL) or Adult T-Cell Leukemia/Lymphomas (ATLL)

Blood2021-11-053 citations

Decrease post-transplant relapse using donor-derived expanded NK-cells

Leukemia2021-07-2696 citations

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Blood2019-11-134 citations

Abstract CT216: Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system

Cancer Research2019-07-011 citations

MRI based radiomic signature to predict treatment response to intraventricular natural killer (NK) cell infusion therapy for recurrent/refractory pediatric brain tumors.

Journal of Clinical Oncology2019-05-201 citations

Enhanced antitumor effect and lower viral reactivation with high doses of <i>ex vivo</i> expanded NK cells administered after haploidentical transplantation.

Journal of Clinical Oncology2019-03-101 citations

Phase II study of ex vivo expanded cord blood natural killer cells for multiple myeloma.

Journal of Clinical Oncology2018-05-2011 citations

Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation

Blood2017-12-073 citations

Abstract CT033: Phase I study of intraventricular infusions of autologous exvivo expanded NK cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system

Cancer Research2017-07-01

Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial

Blood2016-12-024 citations

TB-08MECHANISMS OF IMMUNE RESISTANCE IN PEDIATRIC POSTERIOR FOSSA TUMORS

Neuro-Oncology2016-06-011 citations

Phase II trial of umbilical cord blood-derived natural killer cells for multiple myeloma.

Journal of Clinical Oncology2016-05-20

Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias

Blood2015-12-034 citations